Azoospermia — no sperm in the ejaculate — affects roughly 1% of all men and 10–15% of men being evaluated for infertility. But zero in the ejaculate is not zero in the testis: sperm can be retrieved surgically in 47% of non-obstructive cases, and when sperm is found, ICSI produces a live birth in 24% of cycles.
What Is Azoospermia, and How Is It Confirmed?
A direct-smear examination can miss rare sperm: a handful seen only in the centrifuged pellet is cryptozoospermia, and that distinction changes the treatment plan.
“Azoospermia is defined as the absence of sperm in the ejaculate after centrifugation, and typically requires at least two semen analysis evaluations.” — AUA/ASRM Male Infertility Guideline (2020, amended 2024)
Never diagnosed on one sample: in a survey of 367 clinicians across 49 countries, 81.7% required two semen samples — Global practice patterns in NOA evaluation, 2024. Collect samples after 2–5 days of abstinence, as the semen analysis guide covers.
Data sources: AUA/ASRM male infertility guideline, ASRM, CDC ART reports, SART and PubMed-indexed studies.
Two sub-types drive every decision: obstructive azoospermia (OA) — normal production, blocked exit — in 20–40% of cases, and non-obstructive azoospermia (NOA) — a production problem inside the testis — in 60% (Azoospermia differentiation review, 2025; Clomiphene and hCG before micro-TESE, 2026).
The Three Questions That Define Your Case
- Obstruction (OA) or production problem (NOA)? It decides whether you need a 20-minute aspiration or a microsurgical testicular exploration.
- Is there a treatable genetic or hormonal cause? Hypogonadotropic hypogonadism responds to gonadotropins; Klinefelter syndrome and Y-chromosome microdeletions change counseling, not the retrieval decision.
- Can sperm be retrieved, and what then? Your odds depend on testis volume, diagnosis and surgeon.
Obstructive vs Non-Obstructive: What Is the Difference?
| Feature | Obstructive azoospermia (OA) | Non-obstructive azoospermia (NOA) |
|---|---|---|
| Share of azoospermia cases | ~20–40% | ~60% |
| Where the problem is | Blockage in the epididymis, vas deferens or ejaculatory duct | Sperm production inside the testis |
| Typical testis volume | Normal | Reduced |
| Typical FSH level | Normal | Often elevated |
| Typical procedure | TESA, PESA or MESA (aspiration) | micro-TESE (microdissection testicular sperm extraction) or conventional TESE |
| ICSI outcomes | Similar to non-azoospermic ICSI | Lower, and depends on retrieval success |
The AUA/ASRM rule for the ambiguous middle — normal semen volume, normal testicular volume, no epididymal dilatation and FSH (follicle-stimulating hormone) ≤7.6 IU/L — calls for a diagnostic testicular biopsy: in a 2026 chart review more than two-thirds of such men had histopathology consistent with NOA — Algorithm for azoospermic men with normal FSH, 2026.
The global survey’s clinicians differentiate types mainly by physical examination (76.1%), hormone profiles (69.6%) and semen parameters (68.1%); 34.6% perform diagnostic biopsy selectively.
What Causes Azoospermia?
Obstruction
The most common acquired cause is a previous vasectomy; the other frequent entry diagnosis in the 374-man OA cohort: absence of the vas deferens — van Wely et al., Human Reproduction, 2015.
Others include post-infectious epididymal scarring, ejaculatory duct obstruction, and injuries from inguinal hernia or scrotal surgery.
Congenital absence of the vas deferens (CAVD) occurs in about 0.1% of men; most carry at least one cystic-fibrosis-causing CFTR mutation, so CFTR testing and genetic counseling before conception are standard — Genetics of the congenital absence of the vas deferens, 2021 — though 10–20% of CBAVD cases remain genetically undiagnosed. Even with obstruction, 42% of men with cystic fibrosis had elevated FSH in one multicenter study — Testicular function in males with CF, 2025.
Genetic causes
Klinefelter syndrome (47,XXY) affects about 1 in 600 male births and is the most common chromosomal cause of NOA — Continuity of care in Klinefelter syndrome, 2025; in a 466-man infertility cohort, 15.4% received a genetic diagnosis.
Breakdown: CFTR mutations 31.9%, 47,XXY 30.6%, Y-chromosome microdeletions 19.4%, structural chromosomal anomalies 9.7%, congenital hypogonadotropic hypogonadism 8.3% — Genetic causes of male factor infertility, 2024.
Y-chromosome microdeletions track spermatogenic failure dose-responsively: among 4,714 men evaluated for infertility, 3.31% carried one, rising stepwise from 0.17% with a normal sperm count through 1.13% (mild oligozoospermia) and 5.53% (severe oligozoospermia) to 7.54% in azoospermia — Y microdeletions in Chinese men, 2023. ICSI outcomes with ejaculated sperm in AZFc deletions did not differ from controls — but a deletion causing the father’s infertility can be transmitted to a son.
Hormonal causes
In congenital or acquired hypogonadotropic hypogonadism the pituitary under-signals the testes, and production can often be restarted with medication rather than surgery: among 50 men with prepubertal-onset disease treated with hCG (human chorionic gonadotropin) then recombinant FSH, spermatogenesis was induced in 82.0% at a median 7.5 months, reaching a median 5.2 million/mL with 35% motility and 4% normal morphology — larger baseline testis volume was the only success predictor — Gonadotropin therapy for HH, 2025.
Varicocele
A varicocele need not cause azoospermia, but repairing a clinically significant one changes the odds: a meta-analysis of 18 studies and 468 men with NOA found varicocelectomy increased surgical sperm retrieval (OR 2.65; 95% CI 1.69–4.14) and 43.9% had sperm reappear in the ejaculate, though the live-birth benefit was not significant (OR 2.19; 95% CI 0.99–4.83) — Outcome of varicocele repair in NOA, 2016.
Cancer treatment and medication
Alkylating chemotherapy and pelvic radiotherapy can destroy the germinal epithelium permanently, so sperm banking before the first treatment cycle is the safeguard: among 545 men banking before gonadotoxic treatment, 48% of those with testicular malignancy already had oligozoospermia.
Only 5.3% (29 men) used their frozen sperm, across 48 ART (assisted reproductive technology) cycles producing 15 clinical pregnancies and 10 live births — Sperm banking before gonadotoxic treatment, 2021; for prepubertal boys, testicular tissue cryopreservation follows ESHRE good-practice recommendations.
Exogenous testosterone is contraindicated in men trying to conceive — it suppresses the gonadotropins driving sperm production and is a recurring reason for worsening semen parameters after low-T treatment — Micro-TESE phenotype-guided optimization, 2026.
Idiopathic
A substantial share of NOA has no identified cause after full genetic and hormonal workup; the retrieval decision then rests on testis volume, histology and surgical judgment.
What Tests Does a Proper Workup Include?
| Step | What it is | Why it matters |
|---|---|---|
| Two semen analyses | Centrifuged pellet examined, 2–5 days abstinence | Confirms the diagnosis |
| History and examination | Testis volume, epididymal fullness, varicocele | Predicts retrieval odds |
| Hormone panel | FSH (97.0% of experts), total testosterone (92.9%), LH (luteinizing hormone, 86.9%) | Distinguishes hypogonadotropic hypogonadism |
| Karyotype and Y-chromosome microdeletion testing | Blood test | Requested by 86.2% and 88.3% of experts respectively — but only 66.6% ordered any genetic testing at all |
| Scrotal ultrasound | Testis size, epididymal dilatation, varicocele | Feeds the OA/NOA algorithm |
| CFTR testing | When CBAVD is suspected | Affects the partner’s carrier testing and prenatal counseling |
| Diagnostic biopsy | Usually avoidable | 45.1% of surveyed experts never perform it |
The Questions to Ask Before Agreeing to Surgery
- Which type is this — obstructive or non-obstructive — and on what evidence?
- Micro-TESE or conventional TESE, and why — given that pooled retrieval rates do not differ?
- If this attempt fails: second attempt, donor sperm or another path — fresh or frozen sperm for ICSI?
What Are the Real Odds of Sperm Retrieval?
The pooled NOA baseline is 47% per retrieval; below, what changes it.
| Population | Outcome | Source |
|---|---|---|
| NOA, any TESE technique (117 studies, 21,404 men) | Sperm retrieval 47% per procedure (95% CI 45–49%) | Corona et al., 2019 |
| Klinefelter syndrome (37 studies, 1,248 men) | Sperm retrieval 44% (95% CI 39–48%) | Corona et al., 2017 |
| Testis volume >12.5 mL | Retrieval >60% (86.2% accuracy) | — |
Is Micro-TESE Better Than Conventional TESE?
Micro-TESE is often called the gold standard, but the largest pooled analysis shows no retrieval advantage: 46% (95% CI 43–49%) for conventional TESE versus 46% (95% CI 42–49%) for micro-TESE. What micro-TESE does offer is less tissue removal — relevant to postoperative testosterone and repeat procedures.
What Is a Second Attempt Worth?
Retrieval is not a re-enterable lottery: in a 2025 series it was 64.6% at first micro-TESE and 28.8% at repeat attempts (p < 0.01) — Predictors of retrieval, 2025 — so decide with the first attempt’s histology in hand, not on optimism.
Obstructive Cases: Aspiration, Not Microsurgery
For OA, sperm usually comes from TESA (testicular sperm aspiration), PESA (percutaneous epididymal sperm aspiration) or MESA (microsurgical epididymal sperm aspiration) — and the source matters: in the 374-man OA cohort, live birth was 39% after MESA-ICSI versus 24% after TESE-ICSI (adjusted OR 1.82; 95% CI 1.05–3.67), with female age and ovarian reserve the only significant confounders — van Wely et al., 2015.
A separate comparative study found fertilization, clinical pregnancy and live birth rates similar between TESA and PESA, though PESA yielded a higher top-quality embryo rate — TESA vs PESA in OA, 2022.
Should Hormones Be Used Before micro-TESE?
Current evidence does not support routine hormonal preparation: preoperative clomiphene and hCG left micro-TESE retrieval unchanged — Clomiphene and hCG before micro-TESE, 2026 — and phenotype-directed treatment remains investigational — Optimizing micro-TESE outcomes, 2026.
What Happens After Sperm Is Found?
Retrieval is the gate, not the destination: with sperm in hand, ICSI in NOA delivers the outcomes below.
| Outcome | Rate | Source |
|---|---|---|
| Cumulative clinical pregnancy, per ICSI cycle | 29% (95% CI 25–32%) | — |
| Cumulative live birth, per ICSI cycle | 24% (95% CI 20–28%) | — |
| Clinical pregnancy, fresh vs frozen testicular sperm | 35% vs 20% | — |
| Live birth, fresh vs frozen testicular sperm | 30% vs 20% (not significant when analyzed cumulatively) | — |
| Klinefelter syndrome, clinical pregnancy and live birth after ICSI | 43% and 43% | — |
Two implications: fresh testicular sperm tends to beat frozen — one reason clinics coordinate retrieval with the partner’s stimulation cycle rather than banking in advance — and the female partner’s age remains the dominant variable; the IVF success rates by age guide covers those numbers.
In OA, a 2026 study found micro-TESE and TESA sperm comparable for ICSI: first frozen-thawed transfer clinical pregnancy 70% vs 57%, live birth 67% vs 48% — micro-TESE vs TESA for ICSI, 2026.
What If No Sperm Is Found?
A failed retrieval is a medical finding, not a verdict on your fertility. The realistic paths afterward:
- Repeat retrieval — worth discussing when the first dissection was limited or a reversible factor (varicocele, hormonal profile) has changed.
- Donor sperm with ICSI or IUI (intrauterine insemination) — outcomes approach non-azoospermic treatment; see the donor sperm guide.
- Donor embryo or adoption when neither partner’s gametes can be used.
- Stopping treatment — a legitimate choice.
How Does Azoospermia After Cancer Treatment Differ?
Chemotherapy-induced azoospermia behaves differently: alkylating agents and total-body irradiation damage the spermatogonial stem cell pool, and recovery — when it happens — can take years and is often incomplete. The practical consequence is timing: bank sperm before the first gonadotoxic cycle; a low pre-treatment count is not a reason to skip it.
How Much Does Treatment Cost?
Retrieval is billed separately from the IVF/ICSI cycle, fees vary enormously by country: a Kuwait cost study reported testicular sperm extraction at roughly US$1,600–$3,300, varicocelectomy at US$3,300–$6,600, an outpatient visit at US$130–260 and each hormone test around US$165 — Cost burden of male infertility investigations, 2021.
Those are low-to-middle-income market prices; US and Western European prices for the same procedures run higher. On top sits the ART cycle itself: a US IVF cycle typically runs US$15,000–$30,000 — the IVF cost guide breaks it down by country.
Patient Stories: Three Men, Three Outcomes
Shared with consent; names and identifying details changed.
Case 1: Marcus, 41 — a vasectomy, a new relationship, and a 39% chance
Marcus, from Sacramento, California, had a vasectomy at 32. Ten years later, with a new partner wanting a child, two semen analyses confirmed azoospermia.
His urologist explained two routes: vasectomy reversal — success falls steeply with time since the procedure — or retrieval with ICSI. Normal testis volume and FSH made it obstructive from the start, no biopsy needed, and he chose MESA.
“Nobody tells you that a vasectomy isn’t the end of the story,” Marcus said. “What I needed to hear was that my body was still making sperm — it was just a plumbing problem.”
The first ICSI cycle produced three blastocysts; the fresh transfer failed to implant, a frozen one did — total spend around US$24,000.
Case 2: Yang, 30 — Klinefelter syndrome, micro-TESE, and one frozen embryo
Yang, an engineer from Chengdu, was diagnosed with non-mosaic Klinefelter syndrome (47,XXY) after a year of trying: small testis volume, high FSH, two samples with no sperm.
After karyotype, Y-chromosome microdeletion and hormone testing, the clinic proposed micro-TESE in Bangkok, where it plus a coordinated ICSI cycle cost about a third of the quoted US price. In his case, sperm was found.
“They kept saying ‘if we find sperm’ and I kept hearing ‘when we find sperm’,” Yang said. “The doctor made me repeat the number back to her before she would schedule the surgery. I’m glad she did — I would have blamed myself otherwise.”
The first fresh transfer failed; one frozen blastocyst produced a daughter. Surgery plus two ICSI cycles: about US$9,000.
Case 3: Rafael and Sofia, 36 and 34 — two retrievals, then a different road
Rafael, from Mexico City, had non-obstructive azoospermia with small testes and an elevated FSH. His first micro-TESE found no sperm; because the dissection had been limited to one testis, his surgeon offered a second attempt, which also found nothing.
“Two surgeries in eighteen months. The second time I already knew the answer before they told me,” Rafael said. “What I didn’t know was that we still had options. That conversation came too late for us.”
They switched to donor sperm ICSI through the clinic’s bank; Sofia became pregnant on the second transfer. Two surgeries and two ICSI cycles: about US$13,000. “The child is mine in every way that matters,” Rafael puts it.
FAQ
Q: What is azoospermia, and how common is it?
Absence of sperm in the ejaculate — confirmed on a centrifuged sample — affects about 1% of men and 10–15% of men evaluated for infertility; 20–40% of cases are obstructive, about 60% non-obstructive.
Q: Can a man with azoospermia still have a biological child?
Often, yes — sperm is retrieved surgically in 47% of NOA procedures, and ICSI then produced a cumulative live birth rate of 24% per cycle. In OA, outcomes approach non-azoospermic couples.
Q: What is the difference between obstructive and non-obstructive azoospermia?
In OA the testis produces sperm but a blockage — vasectomy, congenital absence of the vas deferens, infection or ejaculatory duct obstruction — keeps it out; in NOA production itself is impaired.
AUA/ASRM suggests diagnostic biopsy when semen volume, testicular volume and the epididymal examination are normal and FSH is ≤7.6 IU/L — a normal FSH is a clue, not a diagnosis.
Q: Is micro-TESE better than conventional TESE?
Not in retrieval rate: the largest meta-analysis found 46% for conventional TESE versus 46% for micro-TESE, and retrieval rates are independent of age and baseline FSH/testosterone. Micro-TESE does preserve more tissue, while testis volume above 12.5 mL predicted a retrieval rate above 60%.
Q: Can medication restore sperm production?
Sometimes, in one situation: hypogonadotropic hypogonadism, where gonadotropins induced spermatogenesis in 82% of 50 men at a median 7.5 months. For most NOA men, empiric pretreatment has not improved retrieval — 45% with preoperative clomiphene and hCG versus 50% without — and testosterone suppresses production and is contraindicated while trying to conceive.
Q: Should we try a second sperm retrieval if the first one failed?
With realistic expectations: in a 2025 series retrieval was 64.6% at first micro-TESE and 28.8% at repeat attempts, with repeat patients older and hormonally worse. Some men still succeed — but decide from the first procedure’s histology and remaining tissue, not hope.
Q: How much does sperm retrieval cost?
A Kuwait cost study put testicular sperm extraction at roughly US$1,600–$3,300 and varicocelectomy at US$3,300–$6,600 — before the ICSI cycle, which typically runs US$15,000–$30,000 in the United States and substantially less in Thailand, Mexico or Taiwan.
Ask for the retrieval, ICSI and embryo-freezing fees as separate line items, what is refunded if no sperm is found, and the lab’s frozen-thaw survival rate.
Q: What about azoospermia caused by cancer treatment?
Recovery is unpredictable, so banking before the first gonadotoxic cycle is the only reliable protection: nearly half of men banking before testicular cancer treatment already had reduced counts, and only 5.3% used their samples.
How to Plan Your Next Step
Azoospermia rewards a careful first month more than a fast first surgery.
- Confirm and classify before treating — two centrifuged semen analyses, examination including testis volume, a hormone panel, karyotype plus Y-chromosome microdeletion testing; FSH alone will not settle the OA/NOA question.
- Ask the clinic for its retrieval rate and its definition of success — the pooled rate is 47% per TESE procedure in NOA, so a clinic quoting 80% is selecting cases or measuring something else.
- Plan the end point in advance — decide together, before the first surgery, what happens if no sperm is found; the couples who weather it best discussed donor sperm, adoption and stopping in advance.
Comparing clinics for micro-TESE, TESA or ICSI — at home or abroad? Browse verified hospital profiles, see the male infertility and IVF guide, or contact our team.
Disclaimer: educational only — not medical advice. Azoospermia requires evaluation by a licensed urologist or reproductive specialist; retrieval and live birth rates are population data and do not predict any individual’s outcome.
Written by the ProIVF Medical Editorial Team, reviewed by the ProIVF Medical Advisory Board, primary sources linked throughout.
Last updated: September 11, 2026
